1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Artificial Pancreas - Medical Devices Pipeline Assessment, 2016

Artificial Pancreas - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, “Artificial Pancreas - Medical Devices Pipeline Assessment, 2016" provides an overview of Artificial Pancreas currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Artificial Pancreas under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Artificial Pancreas under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Artificial Pancreas - Medical Devices Pipeline Assessment, 2016
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Artificial Pancreas Overview 9
3 Products under Development 10
3.1 Artificial Pancreas - Pipeline Products by Stage of Development 10
3.2 Artificial Pancreas - Pipeline Products by Territory 11
3.3 Artificial Pancreas - Pipeline Products by Regulatory Path 12
3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
3.5 Artificial Pancreas - Ongoing Clinical Trials 14
4 Artificial Pancreas - Pipeline Products under Development by Companies 15
4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development 15
4.2 Artificial Pancreas - Pipeline Products by Stage of Development 17
5 Artificial Pancreas Companies and Product Overview 19
5.1 Admetsys Corporation Company Overview 19
5.1.1 Admetsys Corporation Pipeline Products and Ongoing Clinical Trials Overview 19
5.2 Advanced Biosensors-Ohio, Llc Company Overview 20
5.2.1 Advanced Biosensors-Ohio, Llc Pipeline Products and Ongoing Clinical Trials Overview 20
5.3 Animas Corporation Company Overview 21
5.3.1 Animas Corporation Pipeline Products and Ongoing Clinical Trials Overview 21
5.4 Beta-O2 Technologies Ltd. Company Overview 22
5.4.1 Beta-O2 Technologies Ltd. Pipeline Products and Ongoing Clinical Trials Overview 22
5.5 Bigfoot Biomedical, Inc. Company Overview 26
5.5.1 Bigfoot Biomedical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 26
5.6 BioTex, Inc. Company Overview 27
5.6.1 BioTex, Inc. Pipeline Products and Ongoing Clinical Trials Overview 27
5.7 Boston University Company Overview 28
5.7.1 Boston University Pipeline Products and Ongoing Clinical Trials Overview 28
5.8 Cerco Medical LLC Company Overview 29
5.8.1 Cerco Medical LLC Pipeline Products and Ongoing Clinical Trials Overview 29
5.9 Converge Biotech, Inc. Company Overview 30
5.9.1 Converge Biotech, Inc. Pipeline Products and Ongoing Clinical Trials Overview 30
5.10 Covalor Medical, LLC Company Overview 31
5.10.1 Covalor Medical, LLC Pipeline Products and Ongoing Clinical Trials Overview 31
5.11 De Montfort University Company Overview 32
5.11.1 De Montfort University Pipeline Products and Ongoing Clinical Trials Overview 32
5.12 Debiotech S.A. Company Overview 33
5.12.1 Debiotech S.A. Pipeline Products and Ongoing Clinical Trials Overview 33
5.13 Defymed, Inc. Company Overview 34
5.13.1 Defymed, Inc. Pipeline Products and Ongoing Clinical Trials Overview 34
5.14 Diabeloop Company Overview 36
5.14.1 Diabeloop Pipeline Products and Ongoing Clinical Trials Overview 36
5.15 Giner, Inc. Company Overview 39
5.15.1 Giner, Inc. Pipeline Products and Ongoing Clinical Trials Overview 39
5.16 Imperial College London Company Overview 41
5.16.1 Imperial College London Pipeline Products and Ongoing Clinical Trials Overview 41
5.17 Inreda Diabetic BV Company Overview 46
5.17.1 Inreda Diabetic BV Pipeline Products and Ongoing Clinical Trials Overview 46
5.18 Kencak LLC Company Overview 47
5.18.1 Kencak LLC Pipeline Products and Ongoing Clinical Trials Overview 47
5.19 Medtronic plc Company Overview 48
5.19.1 Medtronic plc Pipeline Products and Ongoing Clinical Trials Overview 48
5.20 Miromatrix Medical Inc. Company Overview 56
5.20.1 Miromatrix Medical Inc. Pipeline Products and Ongoing Clinical Trials Overview 56
5.21 Pacific Diabetes Technologies, Inc. Company Overview 58
5.21.1 Pacific Diabetes Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 58
5.22 Pancreum, LLC Company Overview 59
5.22.1 Pancreum, LLC Pipeline Products and Ongoing Clinical Trials Overview 59
5.23 PharmaCyte Biotech, Inc. Company Overview 61
5.23.1 PharmaCyte Biotech, Inc. Pipeline Products and Ongoing Clinical Trials Overview 61
5.24 Rensselaer Polytechnic Institute Company Overview 63
5.24.1 Rensselaer Polytechnic Institute Pipeline Products and Ongoing Clinical Trials Overview 63
5.25 Schneider Children's Medical Center of Israel Company Overview 65
5.25.1 Schneider Children's Medical Center of Israel Pipeline Products and Ongoing Clinical Trials Overview 65
5.26 TecMed, Inc. Company Overview 69
5.26.1 TecMed, Inc. Pipeline Products and Ongoing Clinical Trials Overview 69
5.27 The University of Newcastle Company Overview 70
5.27.1 The University of Newcastle Pipeline Products and Ongoing Clinical Trials Overview 70
5.28 TypeZero Technologies LLC Company Overview 71
5.28.1 TypeZero Technologies LLC Pipeline Products and Ongoing Clinical Trials Overview 71
5.29 Ultradian Diagnostics LLC Company Overview 75
5.29.1 Ultradian Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview 75
5.30 Universidad Autonoma de Madrid Company Overview 76
5.30.1 Universidad Autonoma de Madrid Pipeline Products and Ongoing Clinical Trials Overview 76
5.31 Universitat Politecnica de Valencia Company Overview 77
5.31.1 Universitat Politecnica de Valencia Pipeline Products and Ongoing Clinical Trials Overview 77
5.32 University of California, San Francisco Company Overview 78
5.32.1 University of California, San Francisco Pipeline Products and Ongoing Clinical Trials Overview 78
5.33 University of California, Santa Barbara Company Overview 79
5.33.1 University of California, Santa Barbara Pipeline Products and Ongoing Clinical Trials Overview 79
5.34 University of Cambridge Company Overview 82
5.34.1 University of Cambridge Pipeline Products and Ongoing Clinical Trials Overview 82
5.35 University of Florida Company Overview 84
5.35.1 University of Florida Pipeline Products and Ongoing Clinical Trials Overview 84
5.36 XERIS Pharmaceuticals, Inc. Company Overview 85
5.36.1 XERIS Pharmaceuticals, Inc. Pipeline Products and Ongoing Clinical Trials Overview 85
6 Artificial Pancreas - Recent Developments 86
7 Appendix 95
7.1 Methodology 95
7.2 About GlobalData 97
7.3 Contact Us 98
7.4 Disclaimer 98

1.1 List of Tables
Table 1: Artificial Pancreas - Pipeline Products by Stage of Development 10
Table 2: Artificial Pancreas - Pipeline Products by Territory 11
Table 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12
Table 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
Table 5: Artificial Pancreas - Ongoing Clinical Trials 14
Table 6: Artificial Pancreas Companies - Pipeline Products by Stage of Development 15
Table 7: Artificial Pancreas - Pipeline Products by Stage of Development 17
Table 8: Admetsys Corporation Pipeline Products and Ongoing Clinical Trials Overview 19
Table 9: Admetsys Smart Pancreas - Product Status 19
Table 10: Admetsys Smart Pancreas - Product Description 19
Table 11: Advanced Biosensors-Ohio, Llc Pipeline Products and Ongoing Clinical Trials Overview 20
Table 12: Artificial Pancreas - Product Status 20
Table 13: Artificial Pancreas - Product Description 20
Table 14: Animas Corporation Pipeline Products and Ongoing Clinical Trials Overview 21
Table 15: Hypoglycemia-Hyperglycemia Minimizer System - Product Status 21
Table 16: Hypoglycemia-Hyperglycemia Minimizer System - Product Description 21
Table 17: Beta-O2 Technologies Ltd. Pipeline Products and Ongoing Clinical Trials Overview 22
Table 18: ßAir Bio-artificial Pancreas - Product Status 23
Table 19: ßAir Bio-artificial Pancreas - Product Description 23
Table 20: Beta-O2 Technologies Ltd. - Ongoing Clinical Trials Overview 24
Table 21: ßAir Bio-artificial Pancreas - An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets within the Bioartificial Pancreas Beta-Air in Patients with Type 1 Diabetes Mellitus 25
Table 22: Bigfoot Biomedical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 26
Table 23: Artificial Pancreas - Product Status 26
Table 24: Artificial Pancreas - Product Description 26
Table 25: BioTex, Inc. Pipeline Products and Ongoing Clinical Trials Overview 27
Table 26: Artificial Pancreas - Product Status 27
Table 27: Artificial Pancreas - Product Description 27
Table 28: Boston University Pipeline Products and Ongoing Clinical Trials Overview 28
Table 29: iLet - Product Status 28
Table 30: iLet - Product Description 28
Table 31: Cerco Medical LLC Pipeline Products and Ongoing Clinical Trials Overview 29
Table 32: Islet Sheet - Product Status 29
Table 33: Islet Sheet - Product Description 29
Table 34: Converge Biotech, Inc. Pipeline Products and Ongoing Clinical Trials Overview 30
Table 35: Bioartificial Pancreas System - Product Status 30
Table 36: Bioartificial Pancreas System - Product Description 30
Table 37: Covalor Medical, LLC Pipeline Products and Ongoing Clinical Trials Overview 31
Table 38: Artificial Pancreas - Product Status 31
Table 39: Artificial Pancreas - Product Description 31
Table 40: De Montfort University Pipeline Products and Ongoing Clinical Trials Overview 32
Table 41: InSmart Artificial Pancreas - Product Status 32
Table 42: InSmart Artificial Pancreas - Product Description 32
Table 43: Debiotech S.A. Pipeline Products and Ongoing Clinical Trials Overview 33
Table 44: Next Generation Artificial Pancreas - Product Status 33
Table 45: Next Generation Artificial Pancreas - Product Description 33
Table 46: Defymed, Inc. Pipeline Products and Ongoing Clinical Trials Overview 34
Table 47: MAILPAN - Product Status 35
Table 48: MAILPAN - Product Description 35
Table 49: Diabeloop Pipeline Products and Ongoing Clinical Trials Overview 36
Table 50: Diabeloop - Product Status 36
Table 51: Diabeloop - Product Description 36
Table 52: Diabeloop - Ongoing Clinical Trials Overview 37
Table 53: Diabeloop - Crossover Evaluation of Glycemic Control Provided for Three Days by the Artificial Pancreas Diabeloop Compared to Conventional Treatment by External Insulin Pump in Patients with Type 1 Diabetes in Sedentary Position, Outstanding Meals and Physical Activity: DIABELOOP WP6.2 38
Table 54: Giner, Inc. Pipeline Products and Ongoing Clinical Trials Overview 39
Table 55: BAPIOS System - Product Status 40
Table 56: BAPIOS System - Product Description 40
Table 57: Imperial College London Pipeline Products and Ongoing Clinical Trials Overview 41
Table 58: Bio-inspired Artificial Pancreas - Product Status 42
Table 59: Bio-inspired Artificial Pancreas - Product Description 42
Table 60: Imperial College London - Ongoing Clinical Trials Overview 43
Table 61: Bio-inspired Artificial Pancreas - A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas 44
Table 62: Bio-inspired Artificial Pancreas - Closed-Loop Glucagon Administration for the Automated Prevention and Treatment of Hypoglycemia 44
Table 63: Bio-inspired Artificial Pancreas - The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps 45
Table 64: Inreda Diabetic BV Pipeline Products and Ongoing Clinical Trials Overview 46
Table 65: Bi-Hormonal Artificial Pancreas - Product Status 46
Table 66: Bi-Hormonal Artificial Pancreas - Product Description 46
Table 67: Kencak LLC Pipeline Products and Ongoing Clinical Trials Overview 47
Table 68: BioArtificial Pancreas - Product Status 47
Table 69: BioArtificial Pancreas - Product Description 47
Table 70: Medtronic plc Pipeline Products and Ongoing Clinical Trials Overview 48
Table 71: Hybrid Closed Loop System - Product Status 49
Table 72: Hybrid Closed Loop System - Product Description 49
Table 73: MiniMed 640G System - Product Status 50
Table 74: MiniMed 640G System - Product Description 50
Table 75: Third-Generation Artificial Pancreas System - Product Status 51
Table 76: Third-Generation Artificial Pancreas System - Product Description 51
Table 77: Medtronic plc - Ongoing Clinical Trials Overview 52
Table 78: Hybrid Closed Loop System - Feasibility Study to Evaluate the Hybrid-logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREMED Trial 53
Table 79: Hybrid Closed Loop System - Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop 53
Table 80: MiniMed 640G System - A Performance Evaluation of the Enlite 3 Sensor 54
Table 81: MiniMed 640G System - Prevention of Hypoglycaemia Using the Minimed 640G System 54
Table 82: MiniMed 640G System - Standardized Evaluation of Subcutaneous Glucose Monitoring Systems under Routine Environmental Conditions 55
Table 83: MiniMed 640G System - Study of Minimed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes at Risk of Severe Hypoglycemia 55
Table 84: Miromatrix Medical Inc. Pipeline Products and Ongoing Clinical Trials Overview 56
Table 85: Miro Pancreas - Product Status 57
Table 86: Miro Pancreas - Product Description 57
Table 87: Pacific Diabetes Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 58
Table 88: Single Indicating electrode Sensing Catheter - Product Status 58
Table 89: Single Indicating electrode Sensing Catheter - Product Description 58
Table 90: Pancreum, LLC Pipeline Products and Ongoing Clinical Trials Overview 59
Table 91: Genesis Artificial Pancreas - Product Status 60
Table 92: Genesis Artificial Pancreas - Product Description 60
Table 93: PharmaCyte Biotech, Inc. Pipeline Products and Ongoing Clinical Trials Overview 61
Table 94: Bio-Artificial Pancreas - Product Status 62
Table 95: Bio-Artificial Pancreas - Product Description 62
Table 96: Rensselaer Polytechnic Institute Pipeline Products and Ongoing Clinical Trials Overview 63
Table 97: Closed-Loop Artificial Pancreas System - Product Status 64
Table 98: Closed-Loop Artificial Pancreas System - Product Description 64
Table 99: Schneider Children's Medical Center of Israel Pipeline Products and Ongoing Clinical Trials Overview 65
Table 100: MD-Logic Artificial Pancreas - Product Status 66
Table 101: MD-Logic Artificial Pancreas - Product Description 66
Table 102: Schneider Children's Medical Center of Israel - Ongoing Clinical Trials Overview 67
Table 103: MD-Logic Artificial Pancreas - Open-label, 3 Center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of 60 Hours Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy at T1D Patients at Home 68
Table 104: TecMed, Inc. Pipeline Products and Ongoing Clinical Trials Overview 69
Table 105: TecMed Artificial Pancreas - Product Status 69
Table 106: TecMed Artificial Pancreas - Product Description 69
Table 107: The University of Newcastle Pipeline Products and Ongoing Clinical Trials Overview 70
Table 108: Closed Glucose-Sensing Insulin-Delivery System - Product Status 70
Table 109: Closed Glucose-Sensing Insulin-Delivery System - Product Description 70
Table 110: TypeZero Technologies LLC Pipeline Products and Ongoing Clinical Trials Overview 71
Table 111: inControl AP - Product Status 71
Table 112: inControl AP - Product Description 71
Table 113: TypeZero Technologies LLC - Ongoing Clinical Trials Overview 72
Table 114: inControl AP - A Trial on Artificial Pancreas to Manage Type 1 diabetes By Automatically Regulating Insulin and Blood Sugar Levels 73
Table 115: inControl AP - Examination of New Control Algorithm of inControl AP 73
Table 116: inControl AP - International Diabetes Closed Loop Trial ("IDCL") 74
Table 117: Ultradian Diagnostics LLC Pipeline Products and Ongoing Clinical Trials Overview 75
Table 118: Artificial Pancreas - Product Status 75
Table 119: Artificial Pancreas - Product Description 75
Table 120: Universidad Autonoma de Madrid Pipeline Products and Ongoing Clinical Trials Overview 76
Table 121: Predictive Rule-Based Algorithm - Product Status 76
Table 122: Predictive Rule-Based Algorithm - Product Description 76
Table 123: Universitat Politecnica de Valencia Pipeline Products and Ongoing Clinical Trials Overview 77
Table 124: ClosedLoop 4Meal Control - Product Status 77
Table 125: ClosedLoop 4Meal Control - Product Description 77
Table 126: University of California, San Francisco Pipeline Products and Ongoing Clinical Trials Overview 78
Table 127: Bioartificial Pancreas - Product Status 78
Table 128: Bioartificial Pancreas - Product Description 78
Table 129: University of California, Santa Barbara Pipeline Products and Ongoing Clinical Trials Overview 79
Table 130: Closed-Loop Artificial Pancreas - Product Status 80
Table 131: Closed-Loop Artificial Pancreas - Product Description 80
Table 132: Pediatric Artificial Pancreas - Product Status 81
Table 133: Pediatric Artificial Pancreas - Product Description 81
Table 134: University of Cambridge Pipeline Products and Ongoing Clinical Trials Overview 82
Table 135: Florence D2A System - Product Status 83
Table 136: Florence D2A System - Product Description 83
Table 137: University of Florida Pipeline Products and Ongoing Clinical Trials Overview 84
Table 138: Bioartificial Pancreas - Type 1 Diabetes - Product Status 84
Table 139: Bioartificial Pancreas - Type 1 Diabetes - Product Description 84
Table 140: XERIS Pharmaceuticals, Inc. Pipeline Products and Ongoing Clinical Trials Overview 85
Table 141: G-Pump - BP - Product Status 85
Table 142: G-Pump - BP - Product Description 85
Table 143: Glossary 96

1.2 List of Figures
Figure 1: Artificial Pancreas - Pipeline Products by Stage of Development 10
Figure 2: Artificial Pancreas - Pipeline Products by Territory 11
Figure 3: Artificial Pancreas - Pipeline Products by Regulatory Path 12
Figure 4: Artificial Pancreas - Pipeline Products by Estimated Approval Date 13
Figure 5: Artificial Pancreas - Ongoing Clinical Trials 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.